AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04238624
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive dabrafenib 150 mg orally twice a day
Trial: NCT04238624
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive trametinib 2 mg orally once a day
Trial: NCT03201757
Drug: ALKS 3831
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine + samidorphan, daily oral dosing
Trial: NCT06572462
Drug: individualized ATG dosing strategy
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
Trial: NCT02141347
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab administered intravenously
Trial: NCT03514589
Drug: nasal Tetracosactide
RxNorm normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioavailability of nasal synacthen compared to IV comparator
Trial: NCT03514589
Drug: IV tetracosactide
RxNorm normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioavailability of nasal synacthen compared to IV comparator
Trial: NCT01159158
Drug: Nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide Tablets 120 mg
Trial: NCT02770040
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
Trial: NCT01348321
Drug: Levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
Trial: NCT00498186
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)
Trial: NCT00003311
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003311
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003311
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01119963
Drug: 17-alpha-hydroxy-progesterone caproate, Makena®
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
Trial: NCT00227747
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01054651
Drug: Artesunate+Sulfamethoxypyrazine/pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01054651
Drug: Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02463825
Drug: Pimozide 2 mg per day
RxNorm normalized name: pimozide 2 MG
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01887353
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take ranolazine 1000 mg tablets twice daily
Trial: NCT02463825
Drug: Pimozide 4 mg per day
RxNorm normalized name: pimozide 4 MG
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03815916
Drug: Gold Nanocrystals
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Trial: NCT00833911
Drug: Tramadol Once A Day
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03952806
Drug: Verdiperstat
RxNorm normalized name: Verdiperstat
DrugBank: Verdiperstat (DB12440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg 2 oral tablets, twice daily
Trial: NCT00710827
Drug: NEBIDO
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
Trial: NCT01888835
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01939639
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 IU Oxytocin, intranasal application 45 min prior to the experiment
Trial: NCT02683863
Drug: BG00012 (DMF) (Tecfidera®.)
RxNorm normalized name: Tecfidera
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
Trial: NCT01303601
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks
Trial: NCT01303601
Drug: Starch
RxNorm normalized name: Starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01496846
Drug: IANB Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
Trial: NCT00603447
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
Trial: NCT00603447
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
Trial: NCT00603447
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
Trial: NCT01496846
Drug: SUP Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
Trial: NCT01496846
Drug: SUP Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
Trial: NCT02820025
Drug: doxapram
RxNorm normalized name: Doxapram
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01805856
Drug: PIPC piperacillin sodium
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01805856
Drug: CEZ, cefazolin sodium
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04162366
Drug: Aprocitentan 25 mg
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use once daily
Trial: NCT00813163
Drug: PEP02
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT02136420
Drug: Promethazine
RxNorm normalized name: Promethazine
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject receives promethazine
Trial: NCT01119963
Drug: Castor Oil (Placebo)
RxNorm normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
Trial: NCT04077515
Drug: Sirolimus(0.8mg/m2)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
Trial: NCT04077515
Drug: Sirolimus(0.7mg/m2)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
Trial: NCT02918357
Drug: Ga-68 labeled PSMA-11 PET
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
Trial: NCT01596907
Drug: cellulose
RxNorm normalized name: Cellulose
DrugBank: Sodium cellulose phosphate (DB06776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
Trial: NCT03570359
Drug: Interferon Beta-1A
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon Beta-1A via inhalation
Trial: NCT00483314
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 g p.o. BID x 60 days
Trial: NCT01839149
Drug: TI-001
RxNorm normalized name: Ti tree oil
DrugBank: Tea tree oil (DB11218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TI-001 is intranasal oxytocin
Trial: NCT03406117
Drug: HAT1
RxNorm normalized name: Hydroxyamphetamine
DrugBank: Hydroxyamphetamine (DB09352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
Trial: NCT00410956
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01207596
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hydromorphone extended release, once daily
Trial: NCT02055482
Drug: Molidustat (BAY85-3934)
RxNorm normalized name: Molidustat
DrugBank: Molidustat (DB15642)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
Trial: NCT00410956
Drug: floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01456780
Drug: Loteprednol
RxNorm normalized name: Loteprednol
DrugBank: Loteprednol (DB00873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops, 1 drop twice a day for 4 weeks
Trial: NCT01456780
Drug: B+L Advanced Eye Relief Lubricant Drop
RxNorm normalized name: Soothe Lubricant Eye Drops
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
Trial: NCT01497444
Drug: hypoxia-activated prodrug TH-302
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01497444
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03548987
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (under the skin) injection of semaglutide once-weekly.
Trial: NCT01304537
Drug: Alpha-1 Antitrypsin 40mg (AAT, Glassia®)
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
Trial: NCT01304537
Drug: Alpha-1 Antitrypsin 60mg (AAT, Glassia®)
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
Trial: NCT01304537
Drug: Alpha-1 Antitrypsin 80mg (AAT, Glassia®)
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
Trial: NCT00105950
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tyrosine kinase inhibitor administered daily at 1500 mg/kg
Trial: NCT01452581
Drug: Voluven
RxNorm normalized name: Voluven
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
Trial: NCT03664661
Drug: BCMA nanobody CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Trial: NCT03826602
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150mg administered orally twice daily
Trial: NCT03826602
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850mg administered orally
Trial: NCT03826602
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500 mg administered intravenously (IV)
Trial: NCT01885364
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
Trial: NCT01885364
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection after pretreatment
Trial: NCT04413279
Drug: Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
Trial: NCT02435901
Drug: alemtuzumab (Campath IH)
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
Trial: NCT02435901
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
Trial: NCT02435901
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
Trial: NCT02435901
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
Trial: NCT02435901
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immunosuppressant to prevent graft vs host disease is given on Day -1.
Trial: NCT02435901
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
Trial: NCT00112723
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00379912
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
Trial: NCT00379912
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
Trial: NCT00379912
Drug: Azacitidine (Monotherapy)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
Trial: NCT00291707
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
Trial: NCT00291707
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: • Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if \>6000 cGy to be delivered)
Trial: NCT02886988
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
Trial: NCT00501241
Drug: ATI-7505
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet,placebo, BID
Trial: NCT00501241
Drug: ATI-7505
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-7505 20 mg BID for 4 weeks
Trial: NCT00501241
Drug: ATI-7505
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 40 mg, BID, $ weeks
Trial: NCT00501241
Drug: ATI-7505
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ATI-7505, BID for 4 weeks